Chronic treatment with insulin-like compounds (IGF1, insulin AspB10) with strong binding affinity towards the IGF1R, decreased the tumor latency time and showed increased MAPK-ERK signaling in a mammary gland mouse model, while insulin glargine and human insulin treatment did not significantly decrease the time for tumor development compared to the vehicle-treated mice [21]. Here, IGF1R is linked to neoplasm.